Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $11.15 in the prior trading day, Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $11.19, up 0.36%. In other words, the price has increased by $0.36 from its previous closing price. On the day, 1.37 million shares were traded. DNA stock price reached its highest trading level at $11.31 during the session, while it also had its lowest trading level at $10.8328.
Ratios:
Our goal is to gain a better understanding of DNA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.41 and its Current Ratio is at 5.41. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.70.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 08 ’25 when HENRY CHRISTIAN O bought 10,000 shares for $10.92 per share.
Coen Steven P. sold 310 shares of DNA for $3,843 on Aug 22 ’25. The insider now owns 11,112 shares after completing the transaction at $12.40 per share. On Aug 06 ’25, another insider, Che Austin, who serves as the Officer of the company, bought 2,200 shares for $14.10 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 662445760 and an Enterprise Value of 575345472. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.87 while its Price-to-Book (P/B) ratio in mrq is 0.96. Its current Enterprise Value per Revenue stands at 2.493 whereas that against EBITDA is -2.493.
Stock Price History:
The Beta on a monthly basis for DNA is 1.52, which has changed by 0.9030613 over the last 52 weeks, in comparison to a change of 0.18189907 over the same period for the S&P500. Over the past 52 weeks, DNA has reached a high of $16.85, while it has fallen to a 52-week low of $5.00. The 50-Day Moving Average of the stock is -7.34%, while the 200-Day Moving Average is calculated to be 14.85%.
Shares Statistics:
The stock has traded on average 1.67M shares per day over the past 3-months and 1713090 shares per day over the last 10 days, according to various share statistics. A total of 43.82M shares are outstanding, with a floating share count of 40.51M. Insiders hold about 27.92% of the company’s shares, while institutions hold 58.35% stake in the company. Shares short for DNA as of 1755216000 were 7101248 with a Short Ratio of 4.26, compared to 1752537600 on 10340727. Therefore, it implies a Short% of Shares Outstanding of 7101248 and a Short% of Float of 15.479999999999999.
Earnings Estimates
The current rating of Ginkgo Bioworks Holdings Inc (DNA) reflects the combined expertise of 3.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$1.27, with high estimates of -$1.17 and low estimates of -$1.36.
Analysts are recommending an EPS of between -$5.16 and -$5.33 for the fiscal current year, implying an average EPS of -$5.25. EPS for the following year is -$4.35, with 3.0 analysts recommending between -$3.51 and -$4.85.
Revenue Estimates
4 analysts predict $38.95M in revenue for the current quarter. It ranges from a high estimate of $40M to a low estimate of $37.5M. As of the current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $89.05MFor the next quarter, 4 analysts are estimating revenue of $40.19M. There is a high estimate of $43.7M for the next quarter, whereas the lowest estimate is $37.08M.
A total of 4 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $181M, while the lowest revenue estimate was $175M, resulting in an average revenue estimate of $177.07M. In the same quarter a year ago, actual revenue was $227.04MBased on 4 analysts’ estimates, the company’s revenue will be $202.57M in the next fiscal year. The high estimate is $210M and the low estimate is $194.9M.